2026-05-05T10:07:37Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/577282025-09-03T10:12:57Zcom_10324_1132com_10324_931com_10324_894col_10324_1205

Fernández Lázaro, Diego Fernández Lázaro, César Ignacio Caballero García, Alberto Córdova Martínez, Alfredo 2022-12-13T08:02:13Z 2022-12-13T08:02:13Z 2018 Revista médica de Chile, 2018; Vol. 146, Nª 12, págs. 1444-1451 0034-9887 https://uvadoc.uva.es/handle/10324/57728 10.4067/s0034-98872018001201444 1444 12 1451 Revista médica de Chile 146 Thalidomide changed the treatment of patients with multiple myeloma, however, its effectiveness has been compromised due to its side effects. New strategies are needed to specifically target the challenges of multiple myeloma through innovative, more effective, and less toxic therapy. The new immunomodulatory (IMiDs) compounds are structural and functional analogs of thalidomide, which were designed to improve the immunomodulatory and anticancer properties and tolerability profiles. We review the development of second generation IMiDs, lenalidomide and pomalidomide, their immunomodulatory and tumoricidal effects, their mechanisms of action, as well as the influence of dexamethasone on their effect and pharmacological resistance. In conclusion, lenalidomide and pomalidomide demonstrate a powerful activity and they are highly effective and well-tolerated treatment options for patients with myeloma, used alone or in combination with dexamethasone. spa info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/4.0/ © Sociedad Médica de Santiago Atribución 4.0 Internacional Multiple myeloma - Treatment Multiple myeloma - Diagnosis Immunology Agentes inmunomoduladores (IMiDs): herramientas para el tratamiento del mieloma múltiple info:eu-repo/semantics/article